INTRODUCTION
Kaposi sarcoma herpesvirus (KSHV), a gammaherpesvirus, was discovered in 1994 by Chang et al.
[1 && ], as the causative agent of AIDS-associated Kaposi sarcoma. It is also called human herpesvirus-8 (HHV-8). KSHV has been implicated as the etiologic agent of all forms of Kaposi sarcoma and several other diseases, including multicentric Castleman disease (MCD), primary effusion lymphoma (PEL) and a newly described syndrome, KSHV inflammatory cytokine syndrome (KICS)
KSHV is a necessary but insufficient etiological agent for these diseases. 
PATHOGENESIS OF KAPOSI SARCOMA HERPESVIRUS-ASSOCIATED MALIGNANCIES
KSHV has evolved strategies to evade innate and specific immunity, induce proliferation, and prevent apoptosis of infected cells. These strategies can promote oncogenesis. KSHV also has pleotropic effects on cell signaling that contribute to oncogenesis and angiogenesis, a hallmark of Kaposi sarcoma. For example, the KSHV protein vFLIP stimulates activation of NF-kB and is implicated in Kaposi sarcoma, KSHV-MCD, and PEL [19,20,21 && ]. Various KSHV proteins promote activation of the AKT and mechanistic target of rapamycin (mTOR) pathways, which promote survival and growth and are upregulated in many cancers [12, [22] [23] [24] . Importantly, sirolimus, an inhibitor of mTOR, can treat Kaposi sarcoma in transplant patients [25, 26] . Expression of latent viral proteins is necessary for survival of PEL cell lines, and repression of specific KSHV latent genes can induce apoptosis [6, 27] . Also, KSHV-encoded miRNAs can increase B-cell proliferation in an animal model and promote survival of infected cells [28] [29] [30] [31] . p53 is wild-type in KSHVinfected cells; however, LANA can inhibit p53 activity [32] . Activation of p53 induces apoptosis in KSHV-infected cells, suggesting that repression of p53 is important for survival of these cells [33] . Human interleukin-6 (hIL-6) is up regulated upon KSHV infection; this is mediated by several KSHV genes, such as vFLIP, kaposin B, and a KSHV Gprotein-coupled receptor [encoded by open reading frame 74 (ORF74)] [34] . Also, KSHV encodes a homolog of hIL-6, viral IL-6 (vIL-6). It is believed that increased IL-6 expression benefits KSHV infection in part by inducing proliferation of B lymphocytes [35, 36] . Additionally, vIL-6 signaling can lead to increased vascular endothelial growth factor expression to stimulate angiogenesis [37] . In contrast to other oncogenic viruses, there is evidence that certain lytic KSHV genes are important in oncogenesis. In particular, several studies have shown that vGPCR (ORF74) is important in the pathogenesis of Kaposi sarcoma [38] .
KAPOSI SARCOMA
Kaposi sarcoma is the most common KSHV-associated tumor. There are four major epidemiologic subtypes: classic; iatrogenic or transplant-associated; endemic or African; and AIDS-related or epidemic. Kaposi sarcoma was first described in elderly men in Mediterranean or Eastern European regions and this form is called 'classic' Kaposi sarcoma. Later on, a high incidence of Kaposi sarcoma in SSA was described [39] . In 1970s, association of Kaposi sarcoma with immunosuppressive therapies such as steroids and cyclosporin was reported, providing initial evidence that immunosuppression is an important cofactor [40] . In 1981, the development of Kaposi sarcoma in young gay men was one of the harbingers of the AIDS epidemic. MSM have a much higher incidence than other HIV-risk groups, suggesting that another etiologic agent was causal; in 1994, KSHV was identified as the etiologic agent. The prevalence of KSHV parallels the incidence of Kaposi sarcoma in various populations. In AIDS, a low CD4 þ count, lack of KSHV T-cell immunity, and HIV viremia are associated with the highest Kaposi sarcoma risk [41] [42] [43] . In the combination antiretroviral therapy (ART) era, Kaposi sarcoma incidence decreased by approximately 80%, but has since stabilized [44] . Kaposi sarcoma incidence in HIV patients remains substantially greater than the general population, even in those on ART with controlled HIV viremia and relatively preserved CD4 þ counts. The number of HIV-infected persons in the USA is increasing and ageing, and it is possible that this may lead to an increase in the incidence of AIDS Kaposi sarcoma. The incidence of Kaposi sarcoma is particularly high in SSA because of the high prevalence of both HIV and KSHV infection; in some SSA countries, Kaposi sarcoma is the most common tumor in men [45] .
The most common presentation of Kaposi sarcoma is multifocal cutaneous macules or nodules commonly involving the lower extremities. Edema, ulceration, bleeding, pain, and secondary infection may cause significant morbidity, and patients often have psychological distress from visible stigmata of AIDS. Nodal, lung, gastrointestinal, bones, and other visceral Kaposi sarcoma may occur. Diagnosis is established with a biopsy showing KSHV-infected spindle cells. Staging requires evaluation of the skin and oral mucosa, whereas evaluation for visceral disease is generally limited to a chest X-ray and stool occult blood test, with additional evaluations prompted by symptoms or abnormal initial tests. Kaposi sarcoma patients were initially staged following the AIDS Clinical Trials Group (ACTG) Oncology Committee criteria, where T stands for tumor burden (T 0 or T 1 ), I for immune status (I 0 or I 1 ) and S for systemic illness (S 0 or S 1 ) [46] . Subscripts 0 and 1 denote good risk and poor risk, respectively. Criteria for poor-risk parameters are as follows: T 1 includes tumors with tumor-associated edema or ulceration, extensive oral or gastrointestinal Kaposi sarcoma, and Kaposi sarcoma in other nonnodal viscera; I 1 includes CD4 þ cell less than 150/mL; and S 1 includes history of opportunistic infections and/or thrush, B symptoms, Karnofsky performance status less than 70, or other HIV-related illnesses. In patients receiving ART, CD4 þ cell counts are less important prognostically, and the ACTG classification has been modified, with T 1 S 1 patients considered poor risk and all others (T 0 S 0 ; T 1 S 0 , or T 0 S 1 ) good risk [47] . Nonetheless, in patients with T 1 Kaposi sarcoma, advanced immunosuppression, as measured by CD4 count less than 100/mL, remains an important predictor of death in some regions [48] . The natural history of Kaposi sarcoma varies. Kaposi sarcoma may worsen or improve spontaneously, often in tandem with changes in underlying immune function. Some patients have an indolent pattern whereas others present with aggressive growth. Patients with rapidly progressive Kaposi sarcoma should be evaluated for concurrent KSHV-MCD, PEL, or KICS (see below). There is no evidence that Kaposi sarcoma can be 'cured', although longterm remissions without continued specific therapy are possible. Initial Kaposi sarcoma treatment should be aimed at correcting the underlying immunodeficiency when present. In HIV patients, this includes ART. In transplant-related Kaposi sarcoma, replacing cyclosporine with sirolimus may lead to disease remission [26] . If Kaposi sarcoma is indolent and not affecting quality of life, patients may be followed with a 'watch and wait' approach. Criteria for systemic treatment, that is, treatment over and above improving immune status, include Kaposi sarcomarelated symptoms, rapidly growing Kaposi sarcoma, or psychological distress from cosmetic disfigurement or stigmatization [47] . Localized treatment is generally avoided, because of its systemic nature and local toxicities. [49] [50] [51] [52] [53] . Paclitaxel is approved by the FDA for patients who fail or do not tolerate this initial approach [54, 55] . Patients with Kaposi sarcoma often require treatment for many years, and current therapies are limited by toxicity or the risk of cumulative anthracycline cardiotoxicity. Effective and less toxic approaches are thus an unmet need. In addition, it will be important to develop effective oral agents for resource-limited settings. Pomalidomide has recently been shown to have promising activity in a Phase I/II trial [56 & ].
MULTICENTRIC CASTLEMAN DISEASE
KSHV-associated MCD is a B-cell lymphoproliferative disorder most common arising in HIV-infected patients. It appears to be more common in the ART era [68] . It is rarely reported in SSA, but this is likely because of substantial under-diagnosis. KSHV-MCD presents with intermittent inflammatory symptoms such as fever, night sweats, weight loss, fatigue, and nonspecific respiratory and gastrointestinal symptoms, along with hepatosplenomegaly, lymphadenopathy and edema. KSHV viral load is elevated during symptomatic flares, and decreases with disease treatment and remission [69] . Laboratory abnormalities include elevated C-reactive protein, hypoalbuminemia, anemia, thrombocytopenia, hyponatremia, and elevated immunoglobulins [69, 70] . There is no consensus definition of a KSHV-MCD flare; different groups use combinations of the symptoms and laboratory abnormalities [71, 72] . KSHV-MCD-associated symptoms are believed to be caused by an excess of cytokines, especially vIL-6, hIL-6, and hIL-10 [69, 73] . Patients with flares can have increased serum levels of vIL-6, hIL-6, or both [73] . There is evidence that vIL-6 can activate hIL-6, and may be the most important driving force [74] .
KSHV-MCD diagnosis generally requires an excisional lymph node biopsy showing expansion of reactive plasma cells interspersed with KSHVinfected plasmablasts, as well as hyalinization of lymphoid follicles and increased capillary proliferation. A substantial subset express vIL-6, and a smaller subset also express other KSHV lytic antigens. Maturing B-cells have high levels of X-box binding protein 1 (XBP-1), and there is an evidence that this can contribute to KSHV-MCD pathogenesis by inducing KSHV lytic activation and directly inducing expression of vIL-6 [10 & ]. KSHV-MCD can wax and wane, but untreated, is generally fatal within 2 years. There is no FDAapproved treatment. ART is indicated in HIV-associated KSHV-MCD but is generally insufficient. Control of HIV viremia, however, may reduce the likelihood of recurrence [75] . Treatment with rituximab or the combination of rituximab and liposomal doxorubicin often leads to clinical remission; prolonged remissions are observed, and this therapy can improve survival [ ]. High-dose zidovudine in combination with valganciclovir targets KSHV-infected cells expressing lytic proteins, and has demonstrated activity in KSHV-MCD, although remissions appear more common with rituximab [79] . Table 2 summarizes the evidence for selected therapeutic options for KSHV-MCD.
PRIMARY EFFUSION LYMPHOMA
PEL is a KSHV-associated aggressive mature monoclonal B-cell lymphoma with a poor outcome [80] . Most cases arise in HIV patients. Although relatively rare, PEL is likely to be under-diagnosed [81] . PEL presents with lymphomatous effusions, most commonly pleural, but also peritoneal, pericardial, and even joint [82] . Extra-cavitary forms can involve the skin, lymph nodes, gastrointestinal, and central nervous system (CNS) [83] . PEL should be considered in any HIV patient with effusions, especially if they have Kaposi sarcoma and/or inflammatory symptoms similar to MCD and laboratory criteria for KICS (described below). Even small effusions should be evaluated. PEL cells generally have immunoglobulin gene rearrangement, but often lack surface immunoglobulin or common B-cell surface markers such as CD19, CD20, or CD79a. A diagnosis of PEL requires the presence of KSHV in the malignant cells; about 80% are coinfected with EBV. The immunophenotypic profile may include CD45, CD30, CD38, CD138, and interferon regulatory factor 4 (IRF4) [83] [84] [85] . In addition to imaging of the chest, abdomen, and pelvis, staging should include brain MRI and lumbar puncture to look for CNS involvement. Serial evaluation of KSHV viral load may provide additional information. Currently, there is no standard therapy. Administration of ART is key component for HIV-infected patients, but is insufficient in itself. Dose-adjusted EPOCH (infusional cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone) or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with ART can yield 2-year survival rates of approximately 30-40% [80, 86] . Preclinical studies of pomalidomide or lenalidomide show activity in PEL cells, due in part to a reduction of IRF4 [87 && ,88 & ]. Interestingly, both lenalidomide and pomalidomide have been shown to inhibit KSHV-induced downregulation of MHC class I expression in PEL cells [88 & ]. A prospective trial using lenalidomide combined with rituximab and DA-EPOCH is being developed. Elevated cytokines such as IL-6 have been shown to correlate with poor prognosis in PEL patients and a substantial proportion meet criteria for KICS (described below) [86] . Even though PEL cells do not express CD20, rituximab should be used to treat PEL in patients with concurrent MCD, and may also be useful in other PEL patients by targeting cytokine production by KSHV-infected nontumor B-cells.
KAPOSI SARCOMA HERPESVIRUS INFLAMMATORY CYTOKINE SYNDROME
Our group observed that some KSHV-infected patients manifested inflammatory symptoms similar to those in KSHV-MCD but did not have KSHV-MCD pathology. We described six such patients in a retrospective analysis [4 & ]. Serum vIL6, hIL-6, IL-10, and serum KSHV viral load were significantly higher than control patients with Kaposi sarcoma and no MCD-like symptoms. Based on this initial study, we have developed a working definition of KICS and have undertaken a prospective study of this condition [89 & ,90] . Our current understanding is that as in KSHV-MCD, the symptoms in these patients are caused by cytokine excess directly or indirectly caused by KSHV infection and not attributable to uncontrolled HIV [89 & ]. KICS patients have a high risk of death, and anemia and hypoalbuminemia were poor prognostic indicators [89 & ]. Many have Kaposi sarcoma and/ or PEL. Unrecognized KICS may be an important cause of death in certain patients with AIDS-associated Kaposi sarcoma. Our findings highlight the importance of recognizing KICS in critically ill patients with HIV/KSHV coinfection and stress the unmet need to develop treatment strategies for this patient population. Table 3 displays the working criteria for KICS. The National Cancer Institute is currently evaluating several strategies to treat KSHVassociated diseases, including KICS (Table 4) .
CONCLUSION
KSHV-associated diseases represent a heterogeneous group of disorders. The principal manifestations are from tumor formation (Kaposi sarcoma and PEL) and from cytokine excess (MCD and KICS). A better understanding and recognition of this cluster of entities is essential for the development of improved prevention and treatment approaches. It will be useful to understand the factors leading to these different diseases in different KSHV-infected patients. Promising efforts to develop effective therapies include targeting specific viral genes, targeting dysregulated cellular pathways, inhibiting abnormal cytokine expression, and immunomodulatory approaches. 
